Grifols launches Xembify in USA

12 December 2019

Spanish plasma-derived medicines company Grifols (GRF: MC) today announced the launch of its latest immunoglobulin (IG) innovation, Xembify (immune globulin subcutaneous human-klhw), the company’s first 20% subcutaneous immunoglobulin therapy for the treatment of patients aged two years and older with primary immunodeficiency (PI).

With proven safety, efficacy, and tolerability, Xembify offers subcutaneous administration to patients in the treatment of PI, which are rare and chronic genetic disorders that occur in people born with an impaired or absent immune system. There are roughly 150,000 patients with PI who may be appropriate for IG therapy.

Strengthening Grifols’ growing IG portfolio for PI treatment, Xembify features a balanced formulation for the treatment of a wide range of PI patients, inclusive of those with risk factors, such as diabetes or cardiac impairment. Xembify was approved by the US Food and Drug Administration (FDA) in July 2019.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK